Browse by Audience
Skip to content
Papers of the Week
Erenumab in chronic migraine: experience from a UK tertiary centre and comparison with other real-world evidence.
Abstract
Chronic migraine is a highly disabling primary headache disorder that is the most common diagnosis of patients seen in tertiary headache centres. Typical oral preventive therapies are associated with many limitations that impact their therapeutic utility. Erenumab was the first available calcitonin gene-related peptide monoclonal antibody (CGRP-mAB) in the UK. It had proven efficacy in migraine prevention in clinical trials and limited real-world data in tertiary settings.